Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common cancer drug help tear duct surgery succeed?

NCT ID NCT07154121

Disease control Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether applying 5-fluorouracil (5-FU) during tear duct surgery can improve success for people with a small tear sac and blocked tear ducts. The trial will enroll 100 adults who need endoscopic dacryocystorhinostomy (En-DCR). Half will get standard surgery plus a 5-FU-soaked sponge at the surgical site; the other half will get standard surgery plus saline. Success is measured by symptom relief and a clear tear duct at six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
5-fluorouracil (5-FU)
What this could lead to
If it works, this could offer a simple, low-cost way to improve surgical success for people with a small tear sac and blocked tear ducts.
What could go wrong
This is a small, early-phase trial with only 100 participants. The drug is applied during surgery, but it may not improve outcomes and could cause side effects like irritation or delayed healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with small lacrimal sac-type PANDO based on clinical symptoms, lacrimal duct irrigation, and CT lacrimal duct angiography (minimum diameter on lacrimal sac angiography ≤3 mm); 2. Patients aged 18 years or older; 3. Patients with no history of drug allergies (including 5-FU, contrast agents, or other substances that may affect participation in this study); 4. Patients who have provided informed consent and signed the informed consent form. Exclusion Criteria: 1. Previously underwent nasolacrimal duct surgery; 2. Nasolacrimal duct obstruction secondary to facial surgery, sinus disease, tumors, trauma, or revision DCR; 3. Severe sinusitis or deviated nasal septum; 4. Acute dacryocystitis; 5. Patients with chronic debilitating conditions such as diabetes, malignant tumors, or malnutrition; 6. Patients with systemic diseases such as sarcoidosis or Wegener's granulomatosis that may promote scar formation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary acquired nasolacrimal duct obstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired tear duct stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary acquired nasolacrimal duct obstruction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongshan Ophthalmic Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.